Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.40.

Several equities research analysts have recently commented on the company. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. HC Wainwright cut their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RVPH. Raymond James Financial Inc. purchased a new stake in shares of Reviva Pharmaceuticals during the 4th quarter valued at about $25,000. Cornerstone Select Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the 4th quarter worth approximately $32,000. Drive Wealth Management LLC purchased a new stake in Reviva Pharmaceuticals during the 4th quarter worth approximately $36,000. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals during the 4th quarter worth approximately $45,000. Finally, Tower Research Capital LLC TRC increased its holdings in Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after purchasing an additional 23,953 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Trading Down 2.3 %

RVPH stock opened at $1.25 on Friday. The company has a market capitalization of $41.80 million, a P/E ratio of -1.13 and a beta of -0.12. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.28. The business has a 50 day simple moving average of $1.79 and a 200-day simple moving average of $1.47.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.